Defronzo, Ralph A

• British Journal of Diabetes Vol. 15 No. 2 (2015) - Editorials
  Rehabilitation of pioglitazone
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 15 No. 4 (2015) - Editorials
  Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 16 No. 3 (2016) - Editorials
  Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 17 No. 3 (2017) - Editorials
  What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 17 No. 4 (2017) - Editorials
  Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 20 No. 1 (2020): June 2020 - Editorials
  Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?
  Abstract  PDF  HTML
• British Journal of Diabetes Vol. 20 No. 1 (2020): June 2020 - Original Research
  Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence
  Abstract  PDF  Erratum  HTML
• British Journal of Diabetes Vol. 20 No. 2 (2020): December 2020 - Editorials
  Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020
  Abstract  PDF  HTML